✦ LIBER ✦

Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials

✍ Scribed by Ernest H Choy,Marina Bendit,Dana McAleer,Feng Liu…

Book ID: 126382339
Publisher: BioMed Central
Year: 2013
Tongue: English
Weight: 362 KB
Volume: 15
Category: Article
ISSN: 1478-6354
DOI: 10.1186/ar4312

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Atacicept in patients with rheumatoid ar

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial

✍ R. F. van Vollenhoven; N. Kinnman; E. Vincent; S. Wax; J. Bathon 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB 👁 2 views

Ocrelizumab, a humanized anti-CD20 monoc

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

✍ Mark C. Genovese; Jeffrey L. Kaine; Mitchell B. Lowenstein; José Del Giudice; An 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

A phase II, randomized, double-blind, pl

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

✍ Michael Yellin; Igor Paliienko; Andra Balanescu; Semen Ter-Vartanian; Vira Tselu 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB

MLN3897 plus methotrexate in patients wi

MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study

✍ Clarissa E. Vergunst; Danielle M. Gerlag; Lisa von Moltke; Michael Karol; Tim Wy 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 3 views

## Abstract ## Objective To assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of the CC chemokine receptor CCR1 antagonist MLN3897 in patients with rheumatoid arthritis (RA) receiving methotrexate (MTX). ## Methods In this phase IIa, proof‐of‐concept study, patients meeting the

LY2439821, a humanized anti–interleukin-

LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

✍ M. C. Genovese; F. Van den Bosch; S. A. Roberson; S. Bojin; I. M. Biagini; Peter 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Atacicept in patients with rheumatoid ar

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

✍ M. C. Genovese; N. Kinnman; G. de La Bourdonnaye; C. Pena Rossi; P. P. Tak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB 👁 2 views